skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Diabetes mellitus and co-morbid depression: treatment with milnacipran results in significant improvement of both diseases (results from the Austrian MDDM study group)

Original Research

(3784) Views  (698) Full article downloads

Authors: Heidemarie Abrahamian, Peter Hofmann, Rudolf Prager, Hermann Toplak

Published Date May 2009 Volume 2009:5 Pages 261 - 266
DOI: http://dx.doi.org/10.2147/NDT.S5421

Heidemarie Abrahamian1, Peter Hofmann2, Rudolf Prager1, Hermann Toplak3

13rd Medical Department, General Hospital Hietzing with Neurological Center Rosenhuegel and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Vienna, Austria; 2Department of Psychiatry, University Hospital, Graz, Austria; 3Department of Internal Medicine, University Hospital, Graz, Austria

Abstract: Co-morbid depression is common in patients with diabetes mellitus and has a negative impact on diabetes self-care, adherence to treatment and the development of complications. Effective treatment of depression has been associated with improvement in metabolic parameters. We evaluated the feasibility of a two question screen for co-morbid depression in diabetic patients and studied the effect of the serotonin norepinephrine reuptake inhibitor antidepressant, milnacipran, on metabolic and psychological parameters in 64 type 2 diabetic patients with co-morbid depression. The severity of depression was evaluated using the Beck Depression Inventory (BDI). Patients received milnacipran, and diabetes was treated according to the guidelines of the Austrian Diabetes Association in a 6-month open label study. Metabolic parameters and BDI were measured at baseline and after 1, 3 and 6 months. 46 patients satisfied the criteria for an antidepressant response (reduction of baseline BDI score of at least 50%). Hemoglobin A1c, fasting blood glucose, body mass index, total and LDL-cholesterol and serum triglyceride levels were all significantly decreased in these patients at the end of the study whereas in antidepressant non-responders these parameters were not significantly changed. Diagnosis and treatment of depression is an important factor for the improvement of metabolic control in patients with type 2 diabetes and co-morbid depression.

Keywords: depression, diabetes, milnacipran, metabolic control, metformin








Readers of this article also read:

Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Brain-derived neurotrophic factor: role in depression and suicide
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Impact of HIV infection and alcohol on cognition: a review
Pre- and postmarathon training habits of nonelite runners
Rift Valley fever virus-infected mosquito ova and associated pathology: possible implications for endemic maintenance
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum